Shree Ganesh Remedies Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 6/6

Shree Ganesh Remedies yıllık ortalama 25.8% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 13.6% annual. Gelirler growing yılda ortalama 20.6% oranında artmaktadır. Shree Ganesh Remedies'in özkaynak karlılığı 20.9% ve net marjı 22.7%'dir.

Anahtar bilgiler

25.8%

Kazanç büyüme oranı

24.6%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	17.5%
Gelir büyüme oranı	20.6%
Özkaynak getirisi	20.9%
Net Marj	22.7%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Shree Ganesh Remedies nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

BSE:540737 Gelir, gider ve kazançlar (INR Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	1,229	279	110
30 Jun 24	1,240	280	92
31 Mar 24	1,259	281	98
31 Dec 23	1,174	220	82
30 Sep 23	1,115	215	78
30 Jun 23	993	189	61
31 Mar 23	902	170	70
31 Dec 22	815	150	74
30 Sep 22	806	148	71
30 Jun 22	763	139	51
31 Mar 22	713	134	48
31 Dec 21	661	126	78
30 Sep 21	582	112	76
30 Jun 21	515	101	74
31 Mar 21	491	98	73
31 Dec 20	499	94	56
30 Sep 20	529	92	74
30 Jun 20	588	99	71
31 Mar 20	648	105	69
31 Dec 19	572	95	55
30 Sep 19	497	86	40
30 Jun 19	425	74	38
31 Mar 19	353	62	37
31 Dec 18	352	56	35
30 Sep 18	350	49	33
30 Jun 18	312	48	35
31 Mar 18	273	47	36
31 Mar 17	199	26	26
31 Mar 16	155	11	24
31 Mar 15	165	13	24
31 Mar 14	183	32	23

Kaliteli Kazançlar: 540737 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 540737 'nin mevcut net kar marjları (22.7%) geçen yılın (19.3%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 540737 şirketinin kazançları son 5 yılda yılda 25.8% oranında önemli ölçüde arttı.

Büyüme Hızlandırma: 540737 'un son bir yıldaki kazanç büyümesi ( 29.4% ) 5 yıllık ortalamasını (yıllık 25.8% ) aşıyor.

Kazançlar vs. Sektör: 540737 geçen yılki kazanç büyümesi ( 29.4% ) Pharmaceuticals sektörünün 19.1% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: 540737 'nin Özsermaye Getirisi ( 20.9% ) yüksek olarak değerlendiriliyor.

Shree Ganesh Remedies Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 6/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2025 earnings released: EPS: ₹4.97 (vs ₹5.32 in 2Q 2024)

Shree Ganesh Remedies Limited to Report Q2, 2025 Results on Oct 29, 2024

First quarter 2025 earnings released: EPS: ₹3.62 (vs ₹3.86 in 1Q 2024)

Shree Ganesh Remedies Limited to Report Q1, 2025 Results on Aug 12, 2024

Full year 2024 earnings released: EPS: ₹22.34 (vs ₹13.86 in FY 2023)

Shree Ganesh Remedies Limited to Report Q4, 2024 Results on May 30, 2024

Recent updates

Second quarter 2025 earnings released: EPS: ₹4.97 (vs ₹5.32 in 2Q 2024)

Shree Ganesh Remedies Limited to Report Q2, 2025 Results on Oct 29, 2024

Shree Ganesh Remedies Limited, Annual General Meeting, Sep 30, 2024

Shree Ganesh Remedies Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: EPS: ₹3.62 (vs ₹3.86 in 1Q 2024)

Shree Ganesh Remedies Limited to Report Q1, 2025 Results on Aug 12, 2024

Full year 2024 earnings released: EPS: ₹22.34 (vs ₹13.86 in FY 2023)

New minor risk - Share price stability

Investor sentiment improves as stock rises 22%

Shree Ganesh Remedies Limited to Report Q4, 2024 Results on May 30, 2024

New minor risk - Market cap size

Shree Ganesh Remedies Limited Announces Company Secretary and Compliance Officer Changes

Third quarter 2024 earnings released: EPS: ₹3.84 (vs ₹3.62 in 3Q 2023)

Shree Ganesh Remedies Limited to Report Q3, 2024 Results on Feb 12, 2024

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

Investor sentiment improves as stock rises 22%

Shree Ganesh Remedies Limited to Report Q2, 2024 Results on Nov 10, 2023

Shree Ganesh Remedies Limited Announces Director Appointments

Investor sentiment improves as stock rises 16%

Upcoming dividend of ₹0.50 per share at 0.1% yield

Shree Ganesh Remedies Limited Proposes Final Dividend for Financial Year 2022-23, Payable on 25 September, 2023

Shree Ganesh Remedies Limited, Annual General Meeting, Sep 18, 2023

First quarter 2024 earnings released: EPS: ₹3.86 (vs ₹2.39 in 1Q 2023)

New major risk - Share price stability

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: ₹13.86 (vs ₹11.16 in FY 2022)

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 16%

Whole Time Director & CFO recently bought ₹1.5m worth of stock

Shree Ganesh Remedies Limited Announces Appointment of Parth Kothia as Chief Financial Officer

Third quarter 2023 earnings released: EPS: ₹3.62 (vs ₹3.50 in 3Q 2022)

Shree Ganesh Remedies Limited Announces Resignation of Suresh Panchal as Chief Financial Officer

Investor sentiment improved over the past week

Second quarter 2023 earnings released: EPS: ₹3.28 (vs ₹2.52 in 2Q 2022)

Shree Ganesh Remedies Limited to Report Q3, 2022 Results on Oct 23, 2022

Upcoming dividend of ₹0.50 per share

Shree Ganesh Remedies Limited, Annual General Meeting, Sep 28, 2022

First quarter 2023 earnings released: EPS: ₹2.39 (vs ₹2.23 in 1Q 2022)

Shree Ganesh Remedies Limited to Report Q1, 2023 Results on Jul 12, 2022

Full year 2022 earnings released: EPS: ₹11.16 (vs ₹8.12 in FY 2021)

Shree Ganesh Remedies Limited Recommends Final Dividend for the Year Ended March 31, 2022

Prakash Zaverbhai Boghra and Kevin Divyesh Thakor agreed to acquire Akshar Jyot Private Limited from Shree Ganesh Remedies Limited (BSE:540737) for INR 1,00,000.

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS ₹2.52 (vs ₹2.58 in 2Q 2021)

Investor sentiment improved over the past week

Shree Ganesh Remedies Limited (BSE:540737) acquired Akshar Jyot Private Limited from its shareholders for INR 0.1 million.

Shree Ganesh Remedies Limited (BSE:540737) entered into an agreement to acquire a 74% stake in Dhari Chemicals Limited for INR 0.07 million.

Upcoming dividend of ₹1.75 per share

Compliance Officer & Company Secretary Aditya Patel has left the company

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Shree Ganesh Remedies Limited Announces Development of New Product

Shree Ganesh Remedies Limited Recommends Final Dividend for the Financial Year Ended March 31, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: ₹183

Shree Ganesh Remedies Limited Announces Board Changes

Shree Ganesh Remedies Limited to Report Q3, 2021 Results on Jan 18, 2021

Investor sentiment improved over the past week

New 90-day high: ₹165

Market bids up stock over the past week

New 90-day high: ₹135

Shree Ganesh Remedies Limited Announces Board Changes

Shree Ganesh Remedies Limited to Report First Half, 2021 Results on Oct 08, 2020

New 90-day high: ₹150

New 90-day high - ₹117

Full year earnings released - EPS ₹11.67

Gelir ve Gider Dağılımı